Amazon To Face Protests, Strikes In 40 Countries During Black Friday Sales
Amazon.com, Inc. (NASDAQ: AMZN) employees across 40 countries plan protests and walkouts during Black Friday sales.
Dogecoin Co-Founder Says He Can’t ‘Comprehend’ Calls For The Joke Crypto He Created In 3 Hours To Hit $1
Dogecoin (CRYPTO: DOGE) co-founder Billy Markus in an open letter on Reddit this week addressed the heightened interest in the cryptocurrency he cre
REITs: Healthcare Or Office? One Performs Better In A Recession (Both Tout Yields Over 5%)
From data gathered on Sept. 30, 2019, healthcare real estate investment trusts (REITs) have earned a trailing ten-year return of 11.6% on average.
Office REITs, however, tend to have an average ten-year return of 9%.
Bill Gates Diversifies His Portfolio With These 2 Blue Chip Dividend Paying Stocks
After the Bill & Melinda Gates Foundation was formally established in 1999, it received an endowment estimated at more than $22 billion in early 2000, ranking as the largest philanthropic trust in the United States.
CZ, You’re Invited To Speak At Benzinga’s Future Of Crypto Event On Dec. 7 In NYC
Changpeng Zhao, commonly referred to as “CZ”, has emerged as one of the most prominent figures in crypto after the FTX bankruptcy and Sam Bankman-Fried’s demise.
Cathie Wood Increases Stake In 4 Stocks By Over 1,000% – Plus 4 New Holdings For Ark
Cathie Wood’s ARK Innovation ETF (ARCA: ARKK) is down roughly 63% year-to-date, compared to the NASDAQ which is down at least 29% year-to-date and the S&P 500 down over 16% year-to-date.
Lantern Pharma Announces Data Highlighting The Anti-Tumor Potency Of Drug Candidate LP-184 For Glioblastoma At The Society For Neuro-oncology Annual Meeting
Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the
AstraZeneca to Present New Data Advancing Its Ambition to Redefine Care at the 2022 San Antonio Breast Cancer Symposium; Twelve Medicines and Potential New Medicines Will Be Featured in 55 Presentations
Data will show clinical opportunity in HR-positive advanced breast cancer for potential first-in-class AKT inhibitor capivasertib and next-generation oral SERD camizestrant. Enhertu data will reinforce potential to set new standards in HER2-targetable disease. Data for antibody drug conjugate datopotamab deruxtecan will demonstrate potential in HR-positive and triple-negative breast cancer.
House Member That Lobbied For PPP Loans In Gaming Just Sold 2 Dividend Stocks
Nevada Democrat Susie Lee sent a letter in April 2020 to the heads of the Treasury Department and Small Business Administration to reconsider their regulatory guidelines that exclude gaming companies from the Paycheck Protection Program (PPP).
Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium
Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the publication of an abstract highlighting new clinical data for zanidatamab, a